Analysis of the patient-reported outcome (PRO) endpoints found in labeling claims of asthma drugs in Europe

M. Caron, M. P. Emery, P. Marquis, E. Piault (Lyon, France; Boston, United States Of America)

Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care
Session: Cost-effectiveness in diagnosis, therapy and care
Session type: Thematic Poster Session
Number: 1186
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Caron, M. P. Emery, P. Marquis, E. Piault (Lyon, France; Boston, United States Of America). Analysis of the patient-reported outcome (PRO) endpoints found in labeling claims of asthma drugs in Europe. Eur Respir J 2007; 30: Suppl. 51, 1186

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Genetic profile and patient-reported outcomes (PROs) in COPD: a systematic review
Source: International Congress 2017 – Assessing functional outcomes in chronic respiratory disease
Year: 2017


STARLINER study, disease behaviour assessed by a wide range of parameters including patient-reported outcomes (PRO) results
Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis
Year: 2021



Late Breaking Abstract - Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve Asthma study
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021


Patterns of risk of death and asthma-related adverse outcomes in adult asthma patients receiving long-acting β2-agonist (LABA) therapy: results from the UK general practice research database (GPRD)
Source: Annual Congress 2009 - Asthma treatment and control strategies in primary care
Year: 2009


Change in asthma management recommendations is associated with reduction of reliever drugs in the real-world setting: a longitudinal retrospective claims data analysis in Burgenland
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020

Oral corticosteroids in asthma exacerbations: Differences between patient-reported data and proxies from claims data
Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life
Year: 2016


Disease awareness in COPD: Analyses of clinical parameters and patient-reported outcome from the SAT study
Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more
Year: 2020


Relative exposure to inhaled steroids (ratio "ICS-to-total asthma therapy"): Concordant data from electronic medical records, claims data and patient-reported outcomes
Source: Annual Congress 2012 - Healthcare utilisation and treatment of asthma and COPD
Year: 2012

SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting ß2-agonist use in asthma
Source: Eur Respir J, 55 (2) 1901858; 10.1183/13993003.01858-2019
Year: 2020



Examination of variations in responder rates in COPD clinical trial outcomes
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013

Persistence to COPD therapies and impact on exacerbations: a French claims data study
Source: International Congress 2018 – Respiratory epidemiology: from COPD to factors that associate with lung function and infections
Year: 2018




Health-related quality of life (HRQL) and patient-reported outcomes (PRO) in COPD patients receiving add-on-therapy with EPs® 7630
Source: Annual Congress 2011 - COPD management
Year: 2011

Astro-Lab project: Assessment of the safety of long-acting beta agonists (LABAs) in asthma by combining health-care databases and direct patient follow-up: Description of the patient pattern in France and in the United-Kingdom (UK)
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013


Cost impact of time to initiation of triple therapy in COPD patients in Japan: A retrospective analysis of healthcare claims data
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017


Global asthma physician & patient (GAPP) survey: satisfaction with current asthma medications in Europe – paediatric findings
Source: Eur Respir J 2006; 28: Suppl. 50, 480s
Year: 2006

DuoResp Spiromax adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD (SPRINT)
Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Year: 2018


Improvement in asthma control and reduction in medical resource use following treatment with montelukast (PRAACTICAL Study)
Source: Eur Respir J 2005; 26: Suppl. 49, 576s
Year: 2005

The long-term clinical and economic impact of COPD exacerbations: an observational study (SHERLOCK)
Source: Virtual Congress 2020 – Prediction and management of outcomes in obstructive diseases
Year: 2020




Asthma severity, poor control, co-morbidities and prior resource use determined omalizumab prescriptions in a nested case-control study with US claims data
Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms
Year: 2015


COPD related fatigue (COPD-RF) as a patient centred outcome tool in COPD: Various predictors and its correlation with other outcome parameters
Source: International Congress 2016 – Monitoring airway diseases with clinical tools
Year: 2016